Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
α radiation emission
DRUG CLASS:
α radiation emission
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
Iomab-ACT (0)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
212Pb-VMT-𝛼-NET (0)
AAA817 (0)
AB001 (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
JNJ-6420 (0)
[212Pb]VMT01 (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
CONV01-α (0)
BAY 2287411 (0)
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
Iomab-ACT (0)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
212Pb-VMT-𝛼-NET (0)
AAA817 (0)
AB001 (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
JNJ-6420 (0)
[212Pb]VMT01 (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
CONV01-α (0)
BAY 2287411 (0)
›
Associations
(14)
News
Trials
Search handles
Search handles
Filter by
Latest
10ms
Fractionated 225Ac-J591 for progressive #mCRPC in patients with prior treatment with 177Lu-PSMA. @DrJonesNauseef @WeillCornell joins @CaPsurvivorship @DanaFarber to discuss this trial in progress dose-escalation study on UroToday > https://t.co/U1xQ14MzxU (@urotoday)
10 months ago
Clinical
|
rosopatamab-225Ac (CONV01-α)
10ms
Fractionated 225Ac-J591 for progressive #mCRPC in patients with prior treatment with 177Lu-PSMA. @DrJonesNauseef @WeillCornell joins @CaPsurvivorship @DanaFarber to discuss this trial in progress dose-escalation study on UroToday > https://t.co/U1xQ14MzxU (@urotoday)
10 months ago
Clinical
|
rosopatamab-225Ac (CONV01-α)
11ms
Always great to speak with @DrScottTagawa of @WeillCornell who shared findings Phase I dose-escalation results of PSMA-targeted radionuclide therapy PSMA-TRT with alpha-radiolabeled antibody 225Ac-J591 & beta-radioligand 177Lu-PSMA I&T @ASCO #ASCO23 #PCsm #ProstateCancer #GUsm (@VJOncology)
11 months ago
P1 data
|
rosopatamab-225Ac (CONV01-α)
11ms
Fractionated 225Ac-J591 for progressive #mCRPC in patients with prior treatment with 177Lu-PSMA. @DrJonesNauseef @WeillCornell joins @CaPsurvivorship @DanaFarber to discuss this trial in progress dose-escalation study on UroToday > https://t.co/U1xQ14MzxU (@urotoday)
11 months ago
Clinical
|
rosopatamab-225Ac (CONV01-α)
2years
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced #ProstateCancer. Presented by @morr316 @sloan_kettering. #GU22 written coverage by @WallisCJD @UofT on UroToday > https://t.co/eToyvbvnqT @ASCO @neerajaiims (@urotoday)
2 years ago
KLK2 (Kallikrein-related peptidase 2)
|
JNJ-6420
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login